APS03118 global clinical study plan_Applied Pharmaceutical Science, Inc.

Return

APS03118 global clinical study plan

APS03118 is the next-generation of selective RET inhibitor that independently developed by APS. APS03118 is a potential best-in-class program with stronger anti-tumor activity and better tolerability compared to other RET inhibitors in preclinical internal head-to-head studies. At present, APS03118 clinical trials has been approved by FDA and NMPA.

Study No.	Phase	Indication	Region	Start time
APS-RET-101	I/II	with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions	US, EU, APAC	undetermined
APS-RET-102	I	with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions	China	November 2022